|
|
Article: ISTA Gets Approvable Letter On Product To Treat Glaucoma.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Washington Editor
ISTA Pharmaceuticals Inc. expects to enter the $1.1 billion U.S. glaucoma market sometime early next year with its once-daily liquid treatment called Istalol.
High hopes for the future came Monday morning when the Irvine, Calif.-based company released a statement saying the FDA issued an approvable letter for Istalol, a formulation of the beta-blocker timolol developed by Senju Pharmaceutical Co. Ltd., of Osaka, Japan.
ISTA's stock (NASDAQ:ISTA) closed Monday at $7.80, up $1.55, or 24.8 percent.
"Timolol is a well-known product in the U.S. used to treat glaucoma, but this is the first liquid form that is truly used ...
Related newspaper, magazine, and journal articles:
|
|
Article: FDA ISSUES APPROVABLE LETTER, ASKS FOR MORE ...
BIOWORLD Today;
March 25, 2005 ;
700+ words
... ... received an approvable letter from the FDA ... CEO, told BioWorld Today. "This was ... In the approvable letter, the FDA ... 26. (See BioWorld Today, March 4 ... we have an approvable letter," Goldstein ...
|
|